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Mortality due to intentional self-harm in South Africa (SA) 
constitutes 0.1% of all-cause mortality and 0.8% of non-natural 
deaths.[1] Data on admissions to intensive care units (ICUs) in SA 
following overdose (OD) are sparse. A 2014 study conducted at Frere 
Hospital in East London, SA, found that 5.6% of ICU admissions 
were related to OD, constituting 25% of all medically related ICU 
admissions.[2] An Australian study reported an ICU admission 
rate between 13% and 22% following an OD.[3] In the USA, 1% of 
emergency admissions are due to drug OD, with ~25% of these 
patients requiring ICU admission.[4] In the 2018 Annual Report 
of the American Association of Poison Control Centers’ National 
Poison Data System, antipsychotics remain the second-largest class of 
drugs – after analgesics – involved in ODs in adults.[5]
Atypical antipsychotics such as quetiapine, olanzapine, 
clozapine and risperidone exert antagonism at serotonin and 
dopamine receptors, warranting their use in bipolar disorder and 
schizophrenia. [6] In addition, they display off-target binding to 
α1-adrenergic receptors that may lead to vasodilation and lowered 
blood pressure.[6] Quetiapine has a greater preponderance to cause 
hypotension than most antipsychotics.[7] A systematic review of 
cardiovascular toxicity associated with atypical antipsychotic OD 
noted tachycardia, hypotension and prolonged QRS intervals as 
common presentations, with hypotension recorded in up to 42% 
of patients presenting with an OD of quetiapine only.[8] Deaths 
from quetiapine OD were estimated to be in the range of 31.3 per 
million prescriptions in England and Wales between 1993 and 
2002.[9] A more recent analysis in Australia between 2006 and 2016 
estimated death as a direct consequence of quetiapine OD to be 
~1.2% in cases where quetiapine was detected post mortem.[10] 
Quetiapine was also implicated as contributory to death in 37.4% 
of polypharmacy ODs in the same analysis.[10] Although some 
international data are available, there remains a paucity of data on 
quetiapine OD in the SA setting. Hypotension is a common and 
often challenging presentation in patients who have taken an OD of 
commonly prescribed medications such as antipsychotics, tricyclic 
antidepressants, beta-blockers or calcium channel blockers.[11] In 
an SA study, hypotension was reported as a frequent indication for 
ICU admission in tricyclic antidepressant OD.[12] Haemodynamic 
monitoring has been recorded as the second most common reason 
for ICU admission following a depressed level of consciousness 
requiring intubation.[13] Previous reports have advocated against the 
use of adrenaline to manage hypotension resistant to intravenous 
fluids (IVF) in quetiapine OD.[7,14] By virtue of its mechanism of 
action, adrenaline use in the setting of quetiapine OD further lowers 
the blood pressure.[14] Adrenaline is a readily available and cost-
effective vasopressor included in the essential medicines list for SA. 
However, adrenaline may not be an effective or pharmacologically 
appropriate vasopressor in all cases of OD-associated hypotension. 
We report a case of a patient who took an OD of quetiapine, an 
atypical antipsychotic, and presented with significant hypotension 
unresponsive to adrenaline.
Case report
A 19-year-old woman was brought to the emergency unit by her 
relatives, following a reported OD of an unknown amount of her 
prescription quetiapine tablets. Her notable past medical history 
included major depressive disorder, generalised anxiety disorder 
with borderline personality traits, and regular cannabis use. No 
co-ingestants were reported.
On initial assessment, her vital signs were within normal limits: 
blood pressure (BP) 116/69 mmHg, heart rate 70 bpm, afebrile, 
respiratory rate 20 breaths per minute, and oxygen saturation 
97% on room air. However, owing to her depressed level of 
consciousness (Glasgow Coma Scale 7/15) and subsequent inability 
to protect her airway, rapid-sequence intubation was performed with 
succinylcholine and ketamine. Her electrocardiogram showed sinus 
tachycardia only, with no other abnormalities such as a prolonged QT 
interval or a widened QRS complex. Her baseline blood results (full 
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blood count, liver function tests, glucose, and urea, creatinine and 
electrolytes) were unremarkable.
Six hours after ingestion, the patient developed hypotension with 
BP 76/37 mmHg and mean arterial pressure (MAP) 50 mmHg. The 
treating doctor initiated an adrenaline infusion: 20 mg of 1:1 000 
adrenaline diluted in 200 mL normal saline, running at 10 mL/h.[15] 
The infusion was titrated up to 28 mL/h in an attempt to improve 
her BP, which did not increase above 84/45 mmHg with MAP 
58  mmHg. The Poisons Information Helpline of the Western Cape 
was contacted regarding the next appropriate management steps, and 
advised the attending clinician to commence noradrenaline as the 
preferred vasopressor of choice in quetiapine OD. The patient’s BP 
subsequently increased to 98/42 mmHg with MAP 64 mmHg. She 
remained stable with MAP >60 mmHg. Noradrenaline was weaned 
and eventually stopped 28 hours after initiation. The patient was 
extubated shortly thereafter and made a full recovery.
Discussion
In the case presented, our patient had profound hypotension follow-
ing quetiapine OD. There was inadequate blood pressure response 
on adrenaline. After commencement of noradrenaline, the blood 
pressure improved significantly and the patient made a full recovery.
Quetiapine is an atypical antipsychotic drug. It is primarily 
an antagonist of 5HT2- and D2-receptors, where it produces its 
antipsychotic and mood-stabilising effects.[16] It also has antagonistic 
effects on histamine (H1) and adrenergic (α1 and α2) receptors, 
although it has a higher potency at α1- than α2-receptors.[16] Potent 
antagonism of α1-receptors is purported to cause the hypotension 
seen in OD.[16] Quetiapine in OD is also more likely than the other 
atypical antipsychotics to produce significant clinical effects such as 
coma, respiratory depression or hypotension.[17]
The incidence of hypotension may be as high as 18% in patients 
with quetiapine OD,[17] and pharmacological management begins 
with the administration of IVF, followed by vasopressors if IVF 
fails. [18] In the SA context, adrenaline is frequently used as the 
first-line vasopressor of choice by attending doctors. However, in 
quetiapine OD, noradrenaline is recommended as the vasopressor 
of choice in the management of hypotension.[14] The rationale for 
the preference of noradrenaline over adrenaline in managing such 
patients is based primarily on their receptor propensities. Adrenaline 
has both β1- and β2-receptor agonist activity in addition to its α1- and 
α2-receptor agonism.[19] Quetiapine OD causes hypotension by potent 
antagonism of α1-receptors, with adrenaline displaying suboptimal 
vasoconstriction owing to not fully displacing quetiapine from the 
α1-receptor. The simultaneous stimulation of presynaptic α2-receptors 
in addition to β2-receptors by adrenaline reduce sympathetic outflow 
by decreasing noradrenaline release from the sympathetic nerve 
endings, and paradoxical vascular smooth-muscle relaxation and 
vasodilation, respectively,[19,20] thereby decreasing systemic vascular 
resistance and further lowering blood pressure.[20] The net effect is 
that the hypotension is unlikely to improve and may even deteriorate 
following the administration of adrenaline in these patients. In 
comparison with adrenaline, noradrenaline has potent α1-agonist 
activity and less affinity for β2-receptors.[21] The vasoconstriction 
mediated by noradrenaline (α1-agonism) is therefore not counteracted 
by peripheral vasodilatation (β2-agonism), and the adverse effect of a 
quetiapine OD on blood pressure is not augmented.[14,22]
Other atypical antipsychotics commonly used in SA, such as 
olanzapine, clozapine and risperidone, may cause hypotension in 
OD. Similar to quetiapine, olanzapine, clozapine and risperidone 
mediate hypotension by α1-adrenergic antagonism.[23] The use of 
vasopressors with β2-receptor agonism could therefore also result 
in refractory hypotension. Tricyclic antidepressants (TCAs) may 
also cause hypotension in OD by α1-adrenergic antagonism, and 
therefore noradrenaline may likewise be a more appropriate 
alternative in these patients.[24,25] Noradrenaline has also been 
shown to be a better vasopressor than dopamine in TCA-induced 
hypotension. [25] Dopamine exerts some of its effects through the 
release of catecholamines, which may be depleted in OD states.[26] It 
may therefore not be a suitable drug to treat refractory hypotension 
in these ODs. On the contrary, in beta-blocker OD, unopposed β- or 
α-receptor stimulation is potentially hazardous, and adrenaline is 
the preferred drug of choice as it possesses both α- and β-receptor 
agonism.[26] Noradrenaline is currently only accessible via Section 
21 approval in SA. Selected hospitals should consider having limited 
stock available to facilitate prompt access to noradrenaline in cases of 
significant quetiapine OD.
Conclusions
Drug ODs are common presentations to emergency units globally, 
and SA is no exception. Knowledge of the specific mechanisms of 
action of these drugs, as well as those of the vasopressors available 
to the attending doctor, is of paramount importance and will 
ensure the appropriate selection of vasopressors when indicated 
and mitigate potential iatrogenic complications. While adrenaline 
is often the first-line vasopressor in hypotension not responding to 
IVF, the recommended vasopressor of choice for quetiapine OD is 
noradrenaline.
Teaching points
• Quetiapine OD commonly presents with hypotension as a result of 
α1-adrenergic receptor antagonism.
• Adrenaline is commonly used as a first-line vasopressor in 
hypotension unresponsive to IVF. However, in quetiapine OD, 
adrenaline may worsen blood pressure owing to presynaptic 
α2- and β2-adrenergic receptor agonism, resulting in reduced 
sympathetic outflow and vasodilation, respectively.
• Noradrenaline is the preferred vasopressor in quetiapine OD 
owing to its potent agonism at α1-adrenergic receptors and 
negligible effects at α2- and β2-receptors.
• In SA, noradrenaline is accessed via Section 21 approval. Selected 
hospitals should consider having stock available to facilitate 
prompt access to noradrenaline in cases of significant quetiapine 
OD.
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